07 December 2011


Adherence clubs for HIV+ patients has been proven a successful model in strengthening their treatment, adherence and outcomes.
Photo:Samantha Reinders

MSF study shows cryptococcal meningitis as leading cause of death, but access to best treatment is a major challenge
The World Health Organisation (WHO) has issued the first-ever guidelines for the treatment of cryptococcal meningitis – a disease ranking among the top causes of death among people living with HIV/AIDS. However, access to some of the WHO-recommended medicines ranges from difficult to non-existent in developing countries.
According to data presented by the international medical humanitarian organisation Doctors Without Borders (MSF) at the ICASA AIDS conference in Addis Ababa, cryptococcal disease is a major cause of illness and death in many parts of Africa. The study looked at the cause of death among 36,664 people started on antiretroviral therapy (ART) in 25  MSF treatment programs in Africa, Asia and Eastern Europe, between 2002 and 2010. In this study, patients infected with extrapulmonary cryptococcosis had a 3.5 times increased risk of dying in the first six months after antiretroviral therapy was started; the greatest risk of all opportunistic infections associated with HIV.

Adherence club meetings are all held in informal and non-threatening environments, such as this one in a Khayalitsha library, or even at a patients’ home. 
Photo:Samantha Reinders

“Our findings show that people living with HIV/AIDS are frequently contracting and dying of cryptococcal disease,” said Dr. Daniel O’Brien, HIV/AIDS Advisor with MSF and one of the authors of the study.  “It’s very good news there are finally clear guidelines for how to diagnose early and treat this disease, but access to the needed drugs remains a big challenge.”
The main drugs recommended by WHO include amphotericin B and flucytosine as first choice, with amphotericin B and fluconazole as alternatives when the firs regimenis unavailable or unaffordable. Access to flucytosine is restricted by the fact that it is not registered in most countries in sub-Saharan Africa, where the HIV burden is highest. Registration barriers also exist for Amphotericin B, and there have been global shortages of the drug, with South Africa and other countries likely to face stock-outs this year.  In South Africa’s KwaZulu Natal province, researchers found that only 35 percent of patients received any amphotericin B at all, with only 8 percent receiving the recommended 2 week treatment course. 
“To address HIV/AIDS properly depends on being able to prevent, diagnose, treat and cure the opportunistic infections that are ultimately causing the AIDS deaths,” said Dr. O’Brien.
 See related background info
For more information or interviews, please contact
Wyger Wentholt,
MSF Communications Advisor
 Based in Kenya
mobile:  +254 789 333 012
office: +254 20 2101628 /-9